Anzeige
Mehr »
Login
Freitag, 01.11.2024 Börsentäglich über 12.000 News von 674 internationalen Medien
Neuer Gold Rekord bei knapp 2.800 USD und Übernahme-Zirkus!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche
ACCESSWIRE
663 Leser
Artikel bewerten:
(2)

TechPrecision Corporation Reports First Quarter 2024 Financial Results

High customer confidence drives strong backlog

WESTMINSTER, MA / ACCESSWIRE / August 21, 2023 / TechPrecision Corporation (NASDAQ:TPCS) ("TechPrecision" or "the Company"), an industry-leading manufacturer of precision, large-scale fabricated and machined metal components and tested systems with customers in the defense and precision industrial sectors, today reported financial results for the first quarter of fiscal year 2024.

"Customer confidence remains high, driving a strong backlog increase. Total consolidated backlog is at a strong $46.3 million as of June 30, 2023. First quarter consolidated net sales were $7.4 million, or 4% higher when compared to $7.1 million in fiscal 2023 first quarter," stated Alexander Shen, TechPrecision's Chief Executive Officer.

"On a consolidated basis, we had a net loss of $527,000. Our Stadco subsidiary reported strong revenue growth with net sales of $3.0 million or 26% higher than the same period a year ago. Stadco gross profit improved, reporting a loss of $588,000 versus a loss of $1.023 million from the same period a year ago, an improvement of $435,000.Ranor reported net sales of $4.5 million or a 5% decrease from the first quarter of fiscal 2023."

"First quarter net sales for Stadco compared favorably with the same period a year ago," Mr. Shen continued. "Our losses have narrowed year over year. With continued revenue growth, we expect gradual improvement in gross profit and gross margin. We expect to deliver our strong backlog of $46.3 million over the course of the next one to three fiscal years with revenue growth and gross margin expansion."

The following summary compares the three months ended June 30, 2023 to the same prior year period:

Consolidated Financial Results - Fiscal 2024 Three Months Ended June 30, 2023

  • Net sales were $7.4 million, an increase of 4% when compared to the same period in fiscal 2023. Net sales at Stadco increased by 26% on a more favorable project mix. Ranor net sales decreased by 5% year over year with a less favorable project mix.
  • Cost of sales were $6.7 million, or 7% higher, due primarily to higher manufacturing costs at Ranor, due to a less favorable project mix.
  • Gross profit was $0.7 million, or 15% lower when compared to the same period last year. Gross profit decreased at Ranor on a less favorable project mix. Losses at Stadco narrowed year over year on improved overall margins on projects, partially offset by increased underabsorbed factory overhead.
  • SG&A was $1.3 million, a decrease of $0.1 million, primarily due to cost reductions at Stadco.
  • Operating loss increased by approximately $22,000 when compared to the same period a year ago.
  • Net loss per share was $ 0.06.

Financial Position

On June 30, 2023, TechPrecision had $0.3 million in cash and cash equivalents, a decrease since March 31, 2023. Working capital was $4.9 million at June 30, 2023 compared to $5.6 million at March 31, 2023 as the Company borrowed more under its revolving line of credit. Total debt at June 30, 2023 and March 31, 2023 was $7.6 million and $6.1 million, respectively.

About TechPrecision Corporation

TechPrecision Corporation, through its wholly owned subsidiaries, Ranor, Inc. and Stadco, manufactures large-scale, metal fabricated and machined precision components and equipment. These products are used in a variety of markets including: defense, aerospace, nuclear, medical, and precision industrial. TechPrecision's goal is to be an end-to-end service provider to its customers by furnishing customized solutions for completed products requiring custom fabrication and machining, assembly, inspection and testing. To learn more about the Company, please visit the corporate website at http://www.techprecision.com. Information on the Company's website or any other website does not constitute a part of this press release.

Safe Harbor Statement

This release contains certain "forward-looking statements" relating to the business of the Company and its subsidiary companies. All statements other than statements of current or historical fact contained in this press release, including statements that express our intentions, plans, objectives, beliefs, expectations, strategies, predictions or any other statements relating to our future activities or other future events or conditions are forward-looking statements. The words "anticipate," "believe," "continue," "could," "estimate," "expect," "intend," "may," "plan," "predict," "project," "prospects," "will," "should," "would" and similar expressions, as they relate to us, are intended to identify forward-looking statements. These statements are based on current expectations, estimates and projections made by management about our business, our industry and other conditions affecting our financial condition, results of operations or business prospects. These statements are not guarantees of future performance and involve risks, uncertainties and assumptions that are difficult to predict. Therefore, actual outcomes and results may differ materially from what is expressed or forecasted in, or implied by, the forward-looking statements due to numerous risks and uncertainties. Factors that could cause such outcomes and results to differ include, but are not limited to, risks and uncertainties arising from: our reliance on individual purchase orders, rather than long-term contracts, to generate revenue; our ability to balance the composition of our revenues and effectively control operating expenses; external factors that may be outside our control, including health emergencies, like epidemics or pandemics, the Russia- Ukraine conflict, price inflation, interest rate increases and supply chain inefficiencies; the availability of appropriate financing facilities impacting our operations, financial condition and/or liquidity; our ability to receive contract awards through competitive bidding processes; our ability to maintain standards to enable us to manufacture products to exacting specifications; our ability to enter new markets for our services; our reliance on a small number of customers for a significant percentage of our business; competitive pressures in the markets we serve; changes in the availability or cost of raw materials and energy for our production facilities; restrictions in our ability to operate our business due to our outstanding indebtedness; government regulations and requirements; pricing and business development difficulties; changes in government spending on national defense; our ability to make acquisitions and successfully integrate those acquisitions with our business; our failure to maintain effective internal controls over financial reporting; general industry and market conditions and growth rates; and other risks discussed in the Company's periodic reports that are filed with the Securities and Exchange Commission and available on its website (www.sec.gov). Any forward-looking statements speak only as of the date on which they are made, and we undertake no obligation to publicly update or revise any forward-looking statements to reflect events or circumstances that may arise after the date of this press release, except as required by applicable law. Investors should evaluate any statements made by us in light of these important factors.

Company Contact:Investor Relations Contact:
Barbara M. LilleyHayden IR
Chief Financial OfficerBrett Maas
TechPrecision CorporationPhone: 646-536-7331
Phone: 978-883-5102Email: brett@haydenir.com
Email: lilleyb@ranor.comWebsite: www.haydenir.com
Website: www.techprecision.com

-- Tables Follow -

TECHPRECISION CORPORATION
CONDENSED CONSOLIDATED BALANCE SHEETS
(UNAUDITED)

June 30, March 31,
2023 2023
ASSETS
Current assets:
Cash and cash equivalents
$271,918 $534,474
Accounts receivable, net
2,965,696 2,336,481
Contract assets
8,651,343 8,947,811
Raw materials
1,635,748 1,692,852
Work-in-process
816,702 719,736
Other current assets
324,457 348,983
Total current assets
14,665,864 14,580,337
Property, plant and equipment, net
15,376,726 13,914,024
Right of use asset, net
5,492,504 5,660,938
Deferred income taxes
2,077,616 1,931,186
Other noncurrent assets, net
121,256 121,256
Total assets
$37,733,966 $36,207,741
LIABILITIES AND STOCKHOLDERS' EQUITY:
Current liabilities:
Accounts payable
$743,933 $2,224,320
Accrued expenses
2,552,449 2,533,185
Contract liabilities
2,853,695 2,333,591
Current portion of long-term lease liability
715,707 711,727
Current portion of long-term debt, net
2,865,387 1,218,162
Total current liabilities
9,731,171 9,020,985
Long-term debt, net
4,603,255 4,749,139
Long-term lease liability
4,963,082 5,143,974
Other noncurrent liability
4,369,762 2,699,492
Total liabilities
23,667,270 21,613,590
Stockholders' Equity:
Common stock - par value $.0001 per share, shares authorized: 50,000,000; Shares issued and outstanding: June 30, 2023 and March 31, 2023 - 8,613,408
861 861
Additional paid in capital
14,949,729 14,949,729
Accumulated deficit
(883,894) (356,439)
Total stockholders' equity
14,066,696 14,594,151
Total liabilities and stockholders' equity
$37,733,966 $36,207,741

TECHPRECISION CORPORATION
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
(UNAUDITED)

Three months ended June 30,
2023 2022
Net sales
$7,371,240 $7,076,357
Cost of sales
6,677,091 6,259,139
Gross profit
694,149 817,218
Selling, general and administrative
1,273,949 1,375,227
Loss from operations
(579,800) (558,009)
Other income (expense), net
1 (33,225)
Interest expense
(94,086) (83,645)
Total other income (expense), net
(94,085) (116,870)
Loss before income taxes
(673,885) (674,879)
Income tax benefit
(146,430) (173,714)
Net loss
$(527,455) $(501,165)
Net loss per share - basic
$(0.06) $(0.06)
Net loss per share - diluted
$(0.06) $(0.06)
Weighted average number of shares outstanding - basic
8,613,408 8,576,863
Weighted average number of shares outstanding - diluted
8,613,408 8,576,863

TECHPRECISION CORPORATION
NET SALES, COST OF SALES, GROSS PROFIT BY SEGMENT (UNAUDITED)

June 30, 2023 June 30, 2022 Changes
(dollars in thousands)
Amount Percent of
Net sales
Amount Percent of
Net sales
Amount Percent
Net sales






Ranor
$4,499 61% $4,726 67% $(227) (5)%
Stadco
2,967 40% 2,350 33% 617 26%
Intersegment elimination
(95) (1)% -- --% (95) nm%
Consolidated Net sales
$7,371 100% $7,076 100% $295 4%
Cost of sales
Ranor
$3,122 43% $2,886 41% $236 8%
Stadco
3,555 48% 3,373 48% 182 5%
Consolidated Cost of sales
$6,677 91% $6,259 89% $418 7%
Gross profit
Ranor
$1,282 17% $1,840 26% $(558) (30)%
Stadco
(588) (8)% (1,023) (14)% 435 43%
Consolidated Gross profit
$694 9% $817 12% $(123) (15)%

nm - not meaningful

TECHPRECISION CORPORATION
CONSOLIDATED STATEMENTS OF CASH FLOWS
(UNAUDITED)

Three Months Ended June 30,
2023 2022
CASH FLOWS FROM OPERATING ACTIVITIES:
Net loss
$(527,455) $(501,165)
Adjustments to reconcile net loss to net cash provided by operating activities:
Depreciation and amortization
559,735 585,361
Amortization of debt issue costs
18,761 13,399
Stock based compensation expense
-- 52,107
Change in contract loss provision
16,170 18,402
Deferred income taxes
(146,430) (173,714)
Change in fair value for contingent consideration
-- (33,474)
Changes in operating assets and liabilities:
Accounts receivable
(629,215) 501,882
Contract assets
296,468 (452,411)
Work-in-process and raw materials
(39,861) (665,192)
Other current assets
24,526 693,394
Accounts payable
(1,480,387) 481,208
Accrued expenses
(167,629) (85,348)
Contract liabilities
520,104 21,083
Other noncurrent liabilities
1,670,270 993,203
Net cash provided by operating activities
115,057 1,448,735
CASH FLOWS FROM INVESTING ACTIVITIES:
Fixed asset deposit
-- (559,000)
Purchases of property, plant, and equipment
(1,854,002) (203,981)
Net cash used in investing activities
(1,854,002) (762,981)
CASH FLOWS FROM FINANCING ACTIVITIES:
Debt issue costs
-- (6,268)
Revolver loan payments and borrowings, net
1,630,000 (987,002)
Payments of principal for leases
(6,191) (16,860)
Repayments of long-term debt
(147,420) (154,125)
Net cash provided by (used in) financing activities
1,476,389 (1,164,255)
Net decrease in cash and cash equivalents
(262,556) (478,501)
Cash and cash equivalents, beginning of period
534,474 1,052,139
Cash and cash equivalents, end of period
$271,918 $573,638

TECHPRECISION CORPORATION
SUPPLEMENTAL INFORMATION
Reconciliation of EBITDA to Net Loss
(UNAUDITED)

The following table provides a reconciliation of EBITDA to net loss, the most directly comparable U.S. GAAP measure reported in our condensed consolidated financial statements for the following periods:

June 30, June 30, Change
(Dollars in thousands)
2023 2022 Amount
Net loss
$(527) $(501) $(26)
Income tax benefit
(146) (174) 28
Interest expense (1)
94 84 10
Depreciation and amortization
560 585 (25)
EBITDA
$(19) $(6) $(13)

(1) Includes amortization of debt issue costs.

SOURCE: TechPrecision Corporation

View source version on accesswire.com:
https://www.accesswire.com/775659/TechPrecision-Corporation-Reports-First-Quarter-2024-Financial-Results

© 2023 ACCESSWIRE
Tenbagger-Chance mit der nächsten BioNTech

Erinnern Sie sich, als Moderna und BioNTech von unbekannten Unternehmen zu globalen Marktführern wurden und frühzeitige Investoren reich belohnt haben?

Die Branche steht vor einem erneuten Innovationsschub – von bahnbrechenden Medikamenten bis hin zu revolutionären Therapien.

Warum sollten Sie dabei sein?

Sie sollten jetzt in Biotech-Aktien einsteigen, weil wir am Beginn einer neuen Ära der medizinischen Innovation stehen könnten! Gen- und Zelltherapien, personalisierte Medizin und bahnbrechende Technologien könnten das Gesundheitswesen revolutionieren – und die Aktienkurse in die Höhe schießen lassen.

Die nächste Erfolgsgeschichte im Biotechbereich warten nur darauf, entdeckt zu werden. Wer jetzt investiert, hat die Chance, von gigantischen Durchbrüchen und enormen Renditen zu profitieren. Warten Sie nicht, bis es zu spät ist - der nächste Biotech-Superstar könnte morgen schon durchstarten!

Verpassen Sie nicht diese Chance!

Fordern Sie sofort unseren brandneuen Biotech-Spezialreport an und erfahren Sie, welche 3 Biotech-Aktien das riesige Potenzial haben, Ihren finanziellen Erfolg zu sichern. Dieser Report ist komplett kostenlos und zeigt Ihnen zukunftsträchtige Investments im Biotech-Sektor.

Handeln Sie jetzt und sichern Sie sich Ihren kostenfreien Report!

Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.